PBDA.F PROTALIX BIOTHERAP.DL-01

Healthcare Biotechnology Frankfurt Exchange
2.63 EUR
Close of Nov 12, 2026
1.41 2.78
Market cap
EUR 222M
P/E
12.5x
P/B
3.25x
ROE
43.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PBDA.F undervalued?

Graham number
Price2.63
Graham value1.96
Premium34.6%

PBDA.F trades 34.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PROTALIX BIOTHERAP.DL-01 fundamental analysis

No fundamental analysis for PROTALIX BIOTHERAP.DL-01 yet.

PROTALIX BIOTHERAP.DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PROTALIX BIOTHERAP.DL-01

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which i…

Full company profile